



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-Dxd [12G9-2] Bulk Size Ab04094-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Human IgG1, Fc Silent™, Kappa

**Clone Number:** 12G9-2

**Alternative Name(s) of Target:** Exatecan derivative; Camptothecin analog

**UniProt Accession Number of Target Protein:**

**Published Application(s):** ELISA

**Published Species Reactivity:** Species independent

**Immunogen:** The original antibody was generated by immunizing BALB/c mice with Dxd-KLH conjugate.

**Specificity:** This antibody binds Dxd, an anti-cancer alkaloid camptothecin analog, which is a potent DNA topoisomerase I (TOP1) inhibitor. By forming a stable ternary complex with TOP1 and DNA, it arrests the cell cycle to S phase, thereby preventing DNA replication and causing cell death. DxD is used for the generation of antibody-drug conjugates for targeted delivery of toxic materials to cancerous cells. A HER2 targeting -DxD drug conjugate (DS-8201a) shows potent antitumor activity in HER2-positive models

**Application Notes:** The binding reactivity of this antibody towards Dxd-KLH and Dxd-BSA conjugates was determined using ELISA. This antibody is capable of binding antibody-drug conjugates ADC-8201 and ADC029 in a competitive ELISA, wherein the antibody was trastuzumab. The binding affinity of this antibody towards Dxd-BSA was determined using surface plasmon resonance (SPR) and it was reported to be  $K_d = 3.38\text{nM}$  (CN115677857).

**Antibody First Published in:** [PMID:](#)

**Note on publication:**

## Product Form

**Size:** 1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without

added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.